Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients.

Details

Serval ID
serval:BIB_3BA27D1EE4D4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients.
Journal
Clinical Nutrition
Author(s)
Bortolotti M., Maiolo E., Corazza M., Van Dijke E., Schneiter P., Boss A., Carrel G., Giusti V.,  K.A., Quo Chong D.G., Buehler T., Kreis R., Boesch C., Tappy L.
ISSN
1532-1983 (Electronic)
ISSN-L
0261-5614
Publication state
Published
Issued date
2011
Volume
30
Number
4
Pages
494-498
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Abstract
Background & aims: High protein diets have been shown to improve hepatic steatosis in rodent models and in high-fat fed humans. We therefore evaluated the effects of a protein supplementation on intrahepatocellular lipids (IHCL), and fasting plasma triglycerides in obese non diabetic women.Methods: Eleven obese women received a 60 g/day whey protein supplement (WPS) for 4-weeks, while otherwise nourished on a spontaneous diet, IHCL concentrations, visceral body fat, total liver volume (MR), fasting total-triglyceride and cholesterol concentrations, glucose tolerance (standard 75 g OGTT), insulin sensitivity (HOMA IS index), creatinine clearance, blood pressure and body composition (bio-impedance analysis) were assessed before and after 4-week WPS.Results: IHCL were positively correlated with visceral fat and total liver volume at inclusion. WPS decreased significantly IHCL by 20.8 +/- 7.7%, fasting total TG by 15 +/- 6.9%, and total cholesterol by 7.3 +/- 2.7%. WPS slightly increased fat free mass from 54.8 +/- 2.2 kg to 56.7 +/- 2.5 kg, p = 0.005). Visceral fat, total liver volume, glucose tolerance, creatinine clearance and insulin sensitivity were not changed.Conclusions: WPS improves hepatic steatosis and plasma lipid profiles in obese non diabetic patients, without adverse effects on glucose tolerance or creatinine clearance. Trial Number: NCT00870077, ClinicalTrials.gov (C) 2011 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Pubmed
Web of science
Create date
09/09/2011 9:44
Last modification date
20/08/2019 13:31
Usage data